Funding Rounds
NeoPhore

NeoPhore Series B (2024, $12M)

NeoPhore

Small molecule neoantigen immuno-oncology therapies developer.

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series B

Raised Amount: $12.17M

Raised Date: 2024-01-01

Investors